OSTEOSET T is a surgical grade calcium sulfate bone graft substituted impregnated with four percent tobramycin sulfate, which is designed to release at a predictable rate and act as a resorbable scaffold for new bone. The substance is available in pellet form and is equivalent to the OSTEOSET bone graft substitute, which does not contain tobramycin.
Pending FDA approval of OSTEOSET T, the company will conduct a clinical study with members of the U.S. military who have suffered combat-related open fractures. The OSTEOSET T is designed to lower reoperation and infection rates, according to the release.
Read the Wright Medical Group release on OSTEOSET T.
Read other coverage on Wright Medical Group:
– Wright Medical Group Launches Valor Ankle Fusion Nail System
– Wright Receives FDA Approval for Conserve Plus Hip Resurfacing System
– Wright Medical Group Reports Net Sales of $127.7M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
